An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk

Lang Wu, Yaohua Yang, Xingyi Guo, Xiao Ou Shu, Qiuyin Cai, Xiang Shu, Bingshan Li, Ran Tao, Chong Wu, Jason B. Nikas, Yanfa Sun, Jingjing Zhu, Monique J. Roobol, Graham G. Giles, Hermann Brenner, Esther M. John, Judith Clements, Eli Marie Grindedal, Jong Y. Park, Janet L. StanfordZsofia Kote-Jarai, Christopher A. Haiman, Rosalind A. Eeles, Wei Zheng, Jirong Long, The PRACTICAL consortium, CRUK Consortium, BPC3 Consortium, CAPS Consortium, PEGASUS Consortium

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)


It remains elusive whether some of the associations identified in genome-wide association studies of prostate cancer (PrCa) may be due to regulatory effects of genetic variants on CpG sites, which may further influence expression of PrCa target genes. To search for CpG sites associated with PrCa risk, here we establish genetic models to predict methylation (N = 1,595) and conduct association analyses with PrCa risk (79,194 cases and 61,112 controls). We identify 759 CpG sites showing an association, including 15 located at novel loci. Among those 759 CpG sites, methylation of 42 is associated with expression of 28 adjacent genes. Among 22 genes, 18 show an association with PrCa risk. Overall, 25 CpG sites show consistent association directions for the methylation-gene expression-PrCa pathway. We identify DNA methylation biomarkers associated with PrCa, and our findings suggest that specific CpG sites may influence PrCa via regulating expression of candidate PrCa target genes.

Original languageEnglish
Article number3905
Number of pages11
JournalNature Communications
Issue number1
Publication statusPublished - 6 Aug 2020
Externally publishedYes

Cite this